Acadia Pharmaceuticals Inc (ACAD) stock
ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 17/3041% below fair value
$18.75+0.61 (+3.36%)
Close on Nov 13, 2026Market cap $3.23BP/E 8.9Yield –
Acadia Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Acadia Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $319.46M, down 7.3% year over year. For fiscal 2025 it was $328.80M, up 8.4% from the year before. Over ten years it grew 16.1% a year on average. The highest annual figure on record is $361.58M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $328.80M | +8.4% |
| FY2024 | Dec 31, 2024 | $303.25M | -13.8% |
| FY2023 | Dec 31, 2023 | $351.62M | -2.8% |
| FY2022 | Dec 31, 2022 | $361.58M | +51.0% |
| FY2021 | Dec 31, 2021 | $239.42M | -25.0% |
| FY2020 | Dec 31, 2020 | $319.13M | +32.8% |
| FY2019 | Dec 31, 2019 | $240.39M | +28.4% |
| FY2018 | Dec 31, 2018 | $187.16M | +25.5% |
| FY2017 | Dec 31, 2017 | $149.19M | +50.3% |
| FY2016 | Dec 31, 2016 | $99.28M | +34.4% |
| FY2015 | Dec 31, 2015 | $73.87M | +21.9% |
| FY2014 | Dec 31, 2014 | $60.60M | +126.8% |
| FY2013 | Dec 31, 2013 | $26.72M | +42.2% |
| FY2012 | Dec 31, 2012 | $18.79M | +8.6% |
| FY2011 | Dec 31, 2011 | $17.31M | -15.9% |
| FY2010 | Dec 31, 2010 | $20.58M | -50.5% |
| FY2009 | Dec 31, 2009 | $41.59M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $76.28M | -13.1% |
| Q2 FY2026 | Jun 30, 2026 | $81.56M | +4.6% |
| Q1 FY2026 | Mar 31, 2026 | $76.87M | -1.8% |
| Q4 FY2025 | Dec 31, 2025 | $84.76M | -15.9% |
| Q3 FY2025 | Sep 30, 2025 | $87.83M | +31.9% |
| Q2 FY2025 | Jun 30, 2025 | $77.95M | +2.3% |
| Q1 FY2025 | Mar 31, 2025 | $78.27M | +31.1% |
| Q4 FY2024 | Dec 31, 2024 | $100.73M | +50.9% |
| Q3 FY2024 | Sep 30, 2024 | $66.61M | -57.6% |
| Q2 FY2024 | Jun 30, 2024 | $76.23M | +29.7% |
| Q1 FY2024 | Mar 31, 2024 | $59.68M | -13.7% |
| Q4 FY2023 | Dec 31, 2023 | $66.74M | -11.9% |
| Q3 FY2023 | Sep 30, 2023 | $156.96M | +93.0% |
| Q2 FY2023 | Jun 30, 2023 | $58.77M | -22.3% |
| Q1 FY2023 | Mar 31, 2023 | $69.14M | -46.3% |
| Q4 FY2022 | Dec 31, 2022 | $75.74M | +13.1% |
| Q3 FY2022 | Sep 30, 2022 | $81.34M | +38.9% |
| Q2 FY2022 | Jun 30, 2022 | $75.65M | +32.9% |
| Q1 FY2022 | Mar 31, 2022 | $128.86M | +126.2% |
| Q4 FY2021 | Dec 31, 2021 | $66.94M | +7.8% |
| Q3 FY2021 | Sep 30, 2021 | $58.57M | -51.2% |
| Q2 FY2021 | Jun 30, 2021 | $56.94M | -11.4% |
| Q1 FY2021 | Mar 31, 2021 | $56.97M | -21.6% |
| Q4 FY2020 | Dec 31, 2020 | $62.12M | +8.0% |
| Q3 FY2020 | Sep 30, 2020 | $120.08M | +91.8% |
| Q2 FY2020 | Jun 30, 2020 | $64.30M | -4.5% |
| Q1 FY2020 | Mar 31, 2020 | $72.64M | +37.2% |
| Q4 FY2019 | Dec 31, 2019 | $57.52M | +19.4% |
| Q3 FY2019 | Sep 30, 2019 | $62.62M | +17.9% |
| Q2 FY2019 | Jun 30, 2019 | $67.32M | +44.5% |
| Q1 FY2019 | Mar 31, 2019 | $52.92M | +34.7% |
| Q4 FY2018 | Dec 31, 2018 | $48.18M | +11.6% |
| Q3 FY2018 | Sep 30, 2018 | $53.11M | +45.8% |
| Q2 FY2018 | Jun 30, 2018 | $46.59M | +36.3% |
| Q1 FY2018 | Mar 31, 2018 | $39.28M | +10.9% |
| Q4 FY2017 | Dec 31, 2017 | $43.18M | +42.9% |
| Q3 FY2017 | Sep 30, 2017 | $36.42M | – |
| Q2 FY2017 | Jun 30, 2017 | $34.18M | – |
| Q1 FY2017 | Mar 31, 2017 | $35.41M | – |
| Q4 FY2016 | Dec 31, 2016 | $30.22M | – |
See a number that looks wrong?